The technology features a polymer material built to control the delivery of biomaterials to selected areas of the body, with a focus on treatment of degenerative spine conditions.
The polymer construct is opened and removed from the anatomic site, leaving only the filler material within the anatomic site.
Crosstrees Medical president and CEO Robert Scribner said the Crosstrees Pod System offers multiple opportunities for improved surgical outcomes for patients with degenerative spine conditions.
The Pod System is being evaluated in an IDE clinical study being conducted in support of a future 510(k) market clearance submission to the US Food and Drug Administration (FDA).
